ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals (SPRY) filed an officer departure notice on May 13, 2026, signaling a potential shift in leadership that warrants context. Beyond the headline, the timing and circumstances of this departure—along with ARS's financing history and equity dilution trajectory—require deeper analysis to assess execution risk. The full $49 Report contextualizes this 8-K within ARS's capital structure, calculates dilution risk scores across recent equity raises, and flags any AI-detected financial stress signals from concurrent filings. The full $49 Report adds 12-month filing history, dilution quantification, and early-warning signals on cash runway and refinancing dependency.